Trevi Therapeutics expects refractory chronic cough data in the second half of next year, IPF Ocean 2 data in the second half of 27, and Ocean 1 data in the first half of 2028. It reported $299 million in cash and no debt.
TRVI · Trevi Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 36%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Trevi Therapeutics ended the third quarter of 2026 with approximately $299 million in cash, cash equivalents and marketable securities, supporting runway into 2030. Ocean 1 and Ocean 2 are underway; RCC results remain guided for the second half of 2027.
Trevi Therapeutics, Inc. began two Phase 3 trials of Haduvio in 2026 and expects $299.4 million in cash, cash equivalents and marketable securities to fund operations into 2030. Nine-month net loss was $52.4 million, and substantial additional capital is needed.
Trevi Therapeutics initiated OCEAN-2 for IPF-related chronic cough in 2026 and aligned with the FDA on a non-IPF ILD Phase 2 trial. The company expects a cash runway into 2030 and reported a $21.5 million net loss for the third quarter.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Trevi initiated the Phase 3 OCEAN-1 (IPF chronic cough) and Phase 2b LAKE (RCC) trials in Q2 2026, plans to initiate Phase 3 OCEAN-2 in Q3 2026, and ended Q2 with $318.9M in cash following an April financing of ~$162.3M net proceeds, extending runway into 2030; R&D spend rose to $15.2M and net loss widened to $17.8M.
- + Initiated Phase 3 OCEAN-1 trial in IPF-related chronic cough in Q2 2026
- + April 2026 financing added ~$162.3M net proceeds; cash of $318.9M extends runway into 2030
- + Recent competitive exit positions Haduvio as a potential first-in-class therapy across all three chronic cough indications
- + JAMA publication of the Phase 2b CORAL trial and all six ATS 2026 submissions accepted, highlighting efficacy across cough frequencies
- − Net loss widened to $17.8M in Q2 2026 from $12.3M in Q2 2025
- − LAKE trial SSRE in Q4 2026 could require sample-size increase of up to 50%
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $299.4M | third quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRVI
this stock
Trevi Therapeutics, Inc.
|
$1.96B | +9.6% | — | — | 11.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 19
Trevi Therapeutics expects refractory chronic cough data in the second half of next year, IPF Ocean 2 data in the second half of 27, and Ocean 1 data in the first half of 2028. It reported $299 million in cash and no debt.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRVI | +0.7% | +6.0% | -1.7% | +1.2% | +9.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +6.2% | +12.3% | +4.0% | +6.5% | +4.6% |